Cargando…
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
BACKGROUND: Hepatitis C virus (HCV) is a leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer, but little is known about the burden of disease caused by the virus. We summarised burden of disease data presently available for Europe, compared the data to current expert estima...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656539/ https://www.ncbi.nlm.nih.gov/pubmed/19161623 http://dx.doi.org/10.1186/1471-2458-9-34 |
_version_ | 1782165522513657856 |
---|---|
author | Mühlberger, Nikolai Schwarzer, Ruth Lettmeier, Beate Sroczynski, Gaby Zeuzem, Stefan Siebert, Uwe |
author_facet | Mühlberger, Nikolai Schwarzer, Ruth Lettmeier, Beate Sroczynski, Gaby Zeuzem, Stefan Siebert, Uwe |
author_sort | Mühlberger, Nikolai |
collection | PubMed |
description | BACKGROUND: Hepatitis C virus (HCV) is a leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer, but little is known about the burden of disease caused by the virus. We summarised burden of disease data presently available for Europe, compared the data to current expert estimates, and identified areas in which better data are needed. METHODS: Literature and international health databases were systematically searched for HCV-specific burden of disease data, including incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and liver transplantation. Data were collected for the WHO European region with emphasis on 22 countries. If HCV-specific data were unavailable, these were calculated via HCV-attributable fractions. RESULTS: HCV-specific burden of disease data for Europe are scarce. Incidence data provided by national surveillance are not fully comparable and need to be standardised. HCV prevalence data are often inconclusive. According to available data, an estimated 7.3–8.8 million people (1.1–1.3%) are infected in our 22 focus countries. HCV-specific mortality, DALY, and transplantation data are unavailable. Estimations via HCV-attributable fractions indicate that HCV caused more than 86000 deaths and 1.2 million DALYs in the WHO European region in 2002. Most of the DALYs (95%) were accumulated by patients in preventable disease stages. About one-quarter of the liver transplants performed in 25 European countries in 2004 were attributable to HCV. CONCLUSION: Our results indicate that hepatitis C is a major health problem and highlight the importance of timely antiviral treatment. However, data on the burden of disease of hepatitis C in Europe are scarce, outdated or inconclusive, which indicates that hepatitis C is still a neglected disease in many countries. What is needed are public awareness, co-ordinated action plans, and better data. European physicians should be aware that many infections are still undetected, provide timely testing and antiviral treatment, and avoid iatrogenic transmission. |
format | Text |
id | pubmed-2656539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26565392009-03-17 HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality Mühlberger, Nikolai Schwarzer, Ruth Lettmeier, Beate Sroczynski, Gaby Zeuzem, Stefan Siebert, Uwe BMC Public Health Research Article BACKGROUND: Hepatitis C virus (HCV) is a leading cause of chronic liver disease, end-stage cirrhosis, and liver cancer, but little is known about the burden of disease caused by the virus. We summarised burden of disease data presently available for Europe, compared the data to current expert estimates, and identified areas in which better data are needed. METHODS: Literature and international health databases were systematically searched for HCV-specific burden of disease data, including incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and liver transplantation. Data were collected for the WHO European region with emphasis on 22 countries. If HCV-specific data were unavailable, these were calculated via HCV-attributable fractions. RESULTS: HCV-specific burden of disease data for Europe are scarce. Incidence data provided by national surveillance are not fully comparable and need to be standardised. HCV prevalence data are often inconclusive. According to available data, an estimated 7.3–8.8 million people (1.1–1.3%) are infected in our 22 focus countries. HCV-specific mortality, DALY, and transplantation data are unavailable. Estimations via HCV-attributable fractions indicate that HCV caused more than 86000 deaths and 1.2 million DALYs in the WHO European region in 2002. Most of the DALYs (95%) were accumulated by patients in preventable disease stages. About one-quarter of the liver transplants performed in 25 European countries in 2004 were attributable to HCV. CONCLUSION: Our results indicate that hepatitis C is a major health problem and highlight the importance of timely antiviral treatment. However, data on the burden of disease of hepatitis C in Europe are scarce, outdated or inconclusive, which indicates that hepatitis C is still a neglected disease in many countries. What is needed are public awareness, co-ordinated action plans, and better data. European physicians should be aware that many infections are still undetected, provide timely testing and antiviral treatment, and avoid iatrogenic transmission. BioMed Central 2009-01-22 /pmc/articles/PMC2656539/ /pubmed/19161623 http://dx.doi.org/10.1186/1471-2458-9-34 Text en Copyright © 2009 Mühlberger et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mühlberger, Nikolai Schwarzer, Ruth Lettmeier, Beate Sroczynski, Gaby Zeuzem, Stefan Siebert, Uwe HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality |
title | HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality |
title_full | HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality |
title_fullStr | HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality |
title_full_unstemmed | HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality |
title_short | HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality |
title_sort | hcv-related burden of disease in europe: a systematic assessment of incidence, prevalence, morbidity, and mortality |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656539/ https://www.ncbi.nlm.nih.gov/pubmed/19161623 http://dx.doi.org/10.1186/1471-2458-9-34 |
work_keys_str_mv | AT muhlbergernikolai hcvrelatedburdenofdiseaseineuropeasystematicassessmentofincidenceprevalencemorbidityandmortality AT schwarzerruth hcvrelatedburdenofdiseaseineuropeasystematicassessmentofincidenceprevalencemorbidityandmortality AT lettmeierbeate hcvrelatedburdenofdiseaseineuropeasystematicassessmentofincidenceprevalencemorbidityandmortality AT sroczynskigaby hcvrelatedburdenofdiseaseineuropeasystematicassessmentofincidenceprevalencemorbidityandmortality AT zeuzemstefan hcvrelatedburdenofdiseaseineuropeasystematicassessmentofincidenceprevalencemorbidityandmortality AT siebertuwe hcvrelatedburdenofdiseaseineuropeasystematicassessmentofincidenceprevalencemorbidityandmortality |